PORTFOLIO

PORTFOLIO COMPANIES

Repertoire Genesis Inc.

  • Chairman & CEO:
    Ryuji Suzuki
  • President & COO:
    Eiichi Yamaguchi

URL:http://www.repertoire.co.jp/index.html

COMPANY PROFILE

Genetic testing and drug discovery using next-generation immune-repertoire diversity profiling.

Repertoire Genesis Inc. provides a service for Next-Gen T cell receptor (TCR)/B cell receptor (BCR) repertoire analysis that is based on unbiased gene amplification technology and bioinformatics. This analysis is quantitatively superior to the conventional one and can be used for a wide variety of applications, e.g., detection of malignant lymphoma and leukemia, identification of antigen-specific TCR/BCR in infections or cancer, and evaluation of efficacy of anti-cancer drugs such as immune checkpoint blockers and cancer immune therapy. This platform is also expected to contribute to efficient developments of novel therapeutic agents such as TCR gene therapy, CAR-T cell therapy and antibody drugs.

COMPANY STORY

Origin

Ryuji Suzuki (former Shionogi employee) developed bioinformatics software for fast and accurate repertoire analysis on immunity cell receptors (TCR / BCR) with his original unbiased gene amplification technology.

Strength

Repertoire Genesis has a unique technology to analyze immune repertoire accurately and comprehensively from both antigen and antibody factors. The company has dramatically improved the efficiency of development of therapeutic drugs and diagnostic agents acting on the immune system by monitoring immune response in-vivo in detail.
Their Analysis services are being used at numerous domestic and overseas research institutes and pharmaceutical companies including The University of Tokyo School of Medicine Hospital and The University of California San Diego. The company strives to further improve the accuracy of analysis by collaborative research.

UTEC value up

UTEC co-founded our company through their know-how and network regarding fostering of venture companies, in addition to their investment. Also, UTEC supported our infrastructure development to accelerate commercialization of technology after startup.
  • Unbiased next-gen T cell receptor (TCR)/ B cell receptor (BCR) repertoire analysis

  • Somatic mutation and neoantigen analysis for super-personalized medicine

RELATED NEWS